Which patients benefit most from T-DXd + pertuzumab in the first line?
Drs. Pegram and Yan unpack DESTINY-Breast09 patient selection, visceral disease burden, and why treating aggressively upfront may save lives.
DESTINY-Breast09 Explained: Who Should Get T-DXd First-Line?
You may also like
Recommended Videos
